Ftse Mib
35.059,00
0,34%
DAX
20.329,94
-0,10%
S&P 500
5.906,26
-0,05%
NASDAQ
19.467,86
-0,11%
Bitcoin
93.988,56
-3,01%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Artelo Biosciences Inc (ARTL) Artelo Biosciences Inc (ARTL) Notizie

ARTL

Artelo Biosciences (ARTL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ARTL
DataOraFonteTitoloSimboloCompagnia
09/12/202415:15GlobeNewswire Inc.Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related AnorexiaNASDAQ:ARTLArtelo Biosciences Inc
18/11/202414:30GlobeNewswire Inc.Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit NASDAQ:ARTLArtelo Biosciences Inc
13/11/202414:30GlobeNewswire Inc.Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration SymposiumNASDAQ:ARTLArtelo Biosciences Inc
12/11/202414:00GlobeNewswire Inc.Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARTLArtelo Biosciences Inc
08/11/202422:31Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARTLArtelo Biosciences Inc
08/11/202422:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ARTLArtelo Biosciences Inc
05/11/202414:30GlobeNewswire Inc.Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” ProgramNASDAQ:ARTLArtelo Biosciences Inc
09/10/202415:00GlobeNewswire Inc.Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16thNASDAQ:ARTLArtelo Biosciences Inc
04/09/202415:00GlobeNewswire Inc.Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ARTLArtelo Biosciences Inc
13/08/202414:00GlobeNewswire Inc.Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARTLArtelo Biosciences Inc
15/07/202414:30GlobeNewswire Inc.Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorNASDAQ:ARTLArtelo Biosciences Inc
03/07/202415:00GlobeNewswire Inc.Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society SymposiumNASDAQ:ARTLArtelo Biosciences Inc
02/07/202415:00GlobeNewswire Inc.Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor PlatformNASDAQ:ARTLArtelo Biosciences Inc
01/07/202415:00GlobeNewswire Inc.Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society SymposiumNASDAQ:ARTLArtelo Biosciences Inc
04/06/202414:30GlobeNewswire Inc.Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain SocietyNASDAQ:ARTLArtelo Biosciences Inc
29/05/202414:30GlobeNewswire Inc.Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24NASDAQ:ARTLArtelo Biosciences Inc
13/05/202414:00GlobeNewswire Inc.Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARTLArtelo Biosciences Inc
10/05/202415:00GlobeNewswire Inc.Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14thNASDAQ:ARTLArtelo Biosciences Inc
23/04/202414:30GlobeNewswire Inc.Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyNASDAQ:ARTLArtelo Biosciences Inc
22/04/202414:30GlobeNewswire Inc.Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeNASDAQ:ARTLArtelo Biosciences Inc
25/03/202413:00GlobeNewswire Inc.Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateNASDAQ:ARTLArtelo Biosciences Inc
12/03/202414:15GlobeNewswire Inc.Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeNASDAQ:ARTLArtelo Biosciences Inc
23/01/202414:30GlobeNewswire Inc.Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral NeuropathyNASDAQ:ARTLArtelo Biosciences Inc
08/01/202414:30GlobeNewswire Inc.Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12NASDAQ:ARTLArtelo Biosciences Inc
05/12/202314:30GlobeNewswire Inc.Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyNASDAQ:ARTLArtelo Biosciences Inc
30/11/202315:00GlobeNewswire Inc.Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyNASDAQ:ARTLArtelo Biosciences Inc
13/11/202314:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARTLArtelo Biosciences Inc
13/11/202314:00GlobeNewswire Inc.Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ARTLArtelo Biosciences Inc
09/11/202315:00GlobeNewswire Inc.Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain CancersNASDAQ:ARTLArtelo Biosciences Inc
02/11/202313:30GlobeNewswire Inc.Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023NASDAQ:ARTLArtelo Biosciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ARTL

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
LDO
Leonardo
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BFF
BFF Bank
BIT
ILTY
Illimity Bank
BIT
RACE
Ferrari NV
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
TRN
Terna Trasmissione Elett...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network